medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 2

<< Back Next >>

Ann Hepatol 2017; 16 (2)

Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C

Stine JG, Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL

Language: English
References: 23
Page: 215-220
PDF size: 141.99 Kb.


ABSTRACT

Introduction and aim. The effect of the new direct acting antiviral drugs (DAAs) for chronic hepatitis C (HCV) on glycemic control is unknown. Materials and methods. We conducted a retrospective cohort study of patients who were treated for chronic HCV with direct-acting antiviral medications at a single academic institution between May 2013 and April 2016. Univariate analysis was performed comparing subjects pre- and post-treatment. Results. One hundred seventy-five consecutive adult patients were treated for chronic HCV and met enrollment criteria. The majority (80.8%) were genotype 1 and overall cohort sustained virologic response at week 12 (SVR12) was 97.8%. Thirty-one (18.5%) had diabetes mellitus (DM); twenty-six had pre- and post-treatment HbA1c values. Of these, 76.9% were male and 61.5% had cirrhosis. Ninety-six percent were prescribed sofosbuvir-based therapy and all but one (96.8%) achieved SVR12. Three patients were started on treatment despite meeting the definition for poorly controlled DM (HbA1c › 9 mg/dL). There was no significant difference when comparing pre-treatment (7.36 mg/dL, 95% CI 6.55-8.16) to post-treatment HbA1c (7.11 mg/dL, 95% CI 6.34-7.88, p = 0.268). Thirty-one percent of subjects required dose escalation or the initiation of insulin based therapy during treatment. Discussion. Although chronic HCV is associated with exacerbation of insulin resistance, our results showed HbA1c to be unaffected by eradication of chronic HCV with DAA in diabetic patients with and without cirrhosis. Paradoxically, almost 1/3 of patients required escalation of anti-diabetic therapy during treatment. Long-term studies are warranted to understand the relationship between HCV viral eradication and insulin metabolism.


REFERENCES

  1. Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World journal of diabetes 2014; 5: 52-58 [PMID: 24567801 PMCID: PMC3932427. DOI: 10.4239/wjd.v5.i1.52].

  2. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-29 [PMID: 23907700. DOI: 10.1002/ hep.26641].

  3. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41.e436 [PMID: 24184810. DOI: 10.1053/ j.gastro.2013.10.058].

  4. Greenberg PD, Rosman AS, Eldeiry LS, Naqvi Z, Brau N. Decline in haemoglobin A1c values in diabetic patients receiving interferon-alpha and ribavirin for chronic hepatitis C. J Viral Hepatitis 2006; 13: 613-617 [PMID: 16907848. DOI: 10.1111/ j.1365-2893.2006.00729.x].

  5. Kawaguchi T, Taniguchi E, Itou M, Sakata M, Sumie S, Sata M. Insulin resistance and chronic liver disease. World J Hepatol 2011; 3: 99-107 [PMID: 21731901 PMCID: PMC3124882. DOI: 10.4254/wjh.v3.i5.99].

  6. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Hepatology 2001; 33: 1554 [PMID: 11391549 DOI: 10.1053/ jhep.2001.0103306le01].

  7. Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. WJG 2016; 22: 1461-76 [PMID: 26819514 PMCID: PMC4721980 DOI: 10.3748/wjg.v22.i4.1461].

  8. Dai CY, Yeh ML, Huang CF, Hou CH, Hsieh MY, Huang JF, Lin IL, et al. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol 2015; 30: 879-884 [PMID: 23808794. DOI: 10.1111/ jgh.12313].

  9. 9 Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004; 27: 1171-1175 [PMID: 15111540].

  10. El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance impairs response to antiviral therapy. WJG 2012; 18: 212-24 [PMID: 22294824 PMCID: PMC3261538. DOI: 10.3748/wjg.v18.i3.212].

  11. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol 2008; 6: 864-876 [PMID: 18585970. DOI: 10.1016/j.cgh.2008.03.024].

  12. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34: 297-305 [PMID: 21623851. DOI: 10.1111/j.1365-2036.2011.04716.x].

  13. Romero-Gomez M, Fernandez-Rodriguez CM, Andrade RJ, Diago M, Alonso S, Planas R, Sola R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721-727 [PMID: 18308416. DOI: 10.1016/ j.jhep.2007.11.022].

  14. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47: 2127-2133 [PMID: 18446789. DOI: 10.1002/hep.22269].

  15. 15 Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-6 [PMID: 17222321. DOI: 10.1111/j.1572- 0241.2006.01038.x].

  16. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-8 [PMID: 19231011 DOI: 10.1016/j.jhep.2008.12.017].

  17. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016 [PMID: 27212241. DOI: 10.1016/j.jhep.2016.05.010].

  18. Deterding K, Honer Zu Siederdissen C, Port K, Solbach P, Sollik L, Kirschner J, Mix C, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 2015; 42: 889-901 [PMID: 26250762. DOI: 10.1111/ apt.13343].

  19. Gonzalez HC, Duarte-Rojo A. Virologic cure of hepatitis C: Impact on hepatic fibrosis and patient outcomes. Current Gastroenterology Reports 2016; 18: 32 [PMID: 27177638. DOI: 10.1007/s11894-016-0508-y].

  20. Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ. Costs and resource utilization associated with anemia and rash in chronic hepatitis c patients treated with directacting antiviral agents in the United States. Clin Ther 2015; 37: 1713-1725.e1713 [PMID: 26111918. DOI: 10.1016/ j.clinthera.2015.05.503].

  21. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 2013; 57: 974-984 [PMID: 23081753. DOI: 10.1002/hep.26096].

  22. Smith MA, Love BL, Mohammad RA. The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy. Expert opinion on drug safety 2015; 14: 1649- 52 [PMID: 26365685. DOI: 10.1517/14740338.2015.1088002].

  23. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54 [PMID: 26111063. DOI: 10.1002/hep.27950].




2020     |     www.medigraphic.com